Human papillomavirus (HPV) vaccine initiation and HPV and vaccine awareness among men 18–26 years in the United States, 2010
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i


Human papillomavirus (HPV) vaccine initiation and HPV and vaccine awareness among men 18–26 years in the United States, 2010
Filetype[PDF-360.55 KB]


Details:
  • Alternative Title:
    Am J Prev Med
  • Description:
    Background In 2009, the quadrivalent Human Papillomavirus (HPV) vaccine was licensed by the Food and Drug Administration (FDA) for use in males 9 through 26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing the administration of HPV vaccine to males 9 through 26 years. Purpose To assess HPV vaccination coverage, evaluate awareness of HPV and HPV vaccine, and identify factors independently associated with awareness of HPV and HPV vaccine among men 18-26 years. Methods We analyzed data from the 2010 National Health Interview Survey (NHIS), to evaluate initiation of HPV vaccination, assess awareness of HPV and the HPV vaccine, and identify factors associated with awareness of HPV and the HPV vaccine among men 18–26 years. Results In 2010, HPV vaccination initiation among men 18-26 years was 1.1%. Among the 1,741 men 18-26 years interviewed, nearly half had heard of HPV (51.8%). Overall, about one third of men 18-26 years had heard of the HPV vaccine (34.8%). Factors independently associated with a higher likelihood of awareness of both HPV and HPV vaccine among men 18-26 years included non-Hispanic white race/ethnicity, higher education, birth in the United States, a greater number of physician contacts, private health insurance, receipt of other vaccines, and reporting risk behaviors related to sexually transmitted diseases, including HIV. Conclusions HPV vaccination initiation among men 18-26 years in 2010 was low. HPV and HPV vaccine awareness were also low and communication messages directed to men are needed. Since ACIP published a recommendation for routine use of HPV4 among males in December 2011, continued monitoring of HPV vaccination uptake among men 18-26 years is useful for evaluating the vaccination campaigns and for planning and implementing strategies for increasing vaccination coverage.
  • Pubmed ID:
    23498097
  • Pubmed Central ID:
    PMC5822442
  • Document Type:
  • Place as Subject:
  • Collection(s):
  • Main Document Checksum:
  • File Type:
No Related Documents.

You May Also Like: